Jupiter Endovascular, Inc., a Menlo Park, CA-based medical technology startup, exited stealth mode with a $21M new round of financing.
Sonder Capital was a key participant in the round that included participation from multiple strategic investors.
The funding will be used to support the company’s upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology.
Jupiter is developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions.
The company has appointed Carl J. St. Bernard as Jupiter Endovascular’s Chief Executive Officer. St. Bernard, an industry veteran with a wealth of medical technology leadership experience, joins Jupiter from Alta Biomaterials, where he held the role of President and CEO. He has over 30 years of experience in the life sciences arena and has held senior executive positions at CeloNova BioSciences, Tryton Medical, Johnson & Johnson Vision, LifeCell, Cordis, and GE Healthcare. He is also an AdvaMed board director.
FinSMEs
15/08/2024